脱氧葛杜宁 | 21963-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 中文名称: 脱氧葛杜宁
• 英文名称: Deoxygedunin
• 英文别名: [(1R,4bR,5R,6aR,10aR,10bR,12aR)-1-(furan-3-yl)-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5,6,6a,10b,11,12-hexahydro-1H-naphtho[2,1-f]isochromen-5-yl] acetate
• CAS: 21963-95-1
• 化学式: C₂₈H₃₄O₆
• 分子量: 466.6
• InChiKey: VOUDTVRGPAGHGA-SQIPALKSSA-N

物化性质

• 沸点：
  586.1±50.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 碰撞截面：
  206.3 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  82.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS<br/>[FR] DÉRIVÉS TRIAZINE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À DES NEUROTROPHINES
  申请人：ALZECURE PHARMA AB

  公开号：WO2021038241A1

  公开（公告）日：2021-03-04

  There is provided a compound of formula I, (I) wherein R1 and R2 are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

  提供了一个式I的化合物，其中R1和R2如本文所定义，这些化合物在治疗由神经营养因子和/或其他营养因子信号传导受损引起的疾病中很有用，如阿尔茨海默病等。
• [EN] TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES<br/>[FR] DÉRIVÉS DE TRIAZINETRIONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA NEUROTROPHINE ET DE TYROSINES KINASES RÉCEPTRICES
  申请人：STIFTELSEN ALZECURE

  公开号：WO2018115891A1

  公开（公告）日：2018-06-28

  The present invention relates to a new use of 4-phenoxy-phenyl-1,3,5-triazine derivatives or pharmaceutically acceptable salts thereof, according to formula I, wherein R1, R2 and U have meanings as provided in the description, as medicaments for the treatment and/or prevention of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors. In particular, the invention relates to the treatment of such diseases in patients with the Val66Met mutation in the brain-derived neurotrophic factor gene.

  本发明涉及4-苯氧基-苯基-1,3,5-三嗪衍生物或其药学上可接受的盐的新用途，其化学式为I，其中R1、R2和U的含义如描述中所提供的，作为治疗和/或预防神经营养因子和/或其他营养因子信号受损的疾病的药物。特别地，本发明涉及治疗患有脑源性神经营养因子基因中Val66Met突变的患者的这种疾病。
• Method of treating pain using agents that promote neuronal differentiation
  申请人：Rusanescu Gabriel

  公开号：US10398760B2

  公开（公告）日：2019-09-03

  The present invention is based on the seminal concept of treating pain by promoting neuronal differentiation. The invention provides a method of treating pain utilizing agents that induce neuronal differentiation by activating specific receptors. The invention also provides a method of screening of agents for the purpose of use in treating pain, based on their neuronal differentiation activity.

  本发明基于通过促进神经元分化来治疗疼痛的开创性概念。本发明提供了一种利用通过激活特定受体诱导神经元分化的制剂治疗疼痛的方法。本发明还提供了一种根据制剂的神经元分化活性筛选用于治疗疼痛的制剂的方法。
• Methods and compositions for treating cancer using P2RX2 inhibitors
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10457740B1

  公开（公告）日：2019-10-29

  The present invention provides methods for treating cancer using P2RX2 inhibitors, such as P2RX2 inhibitory antibodies, among others. The invention also features compositions containing P2RX2 inhibitors, methods of diagnosing patients with P2RX2-associated cancer, and methods of predicting the response of cancer in a subject to treatment with P2RX2 inhibitors.

  本发明提供了使用 P2RX2 抑制剂（如 P2RX2 抑制抗体等）治疗癌症的方法。本发明还包括含有 P2RX2 抑制剂的组合物、诊断 P2RX2 相关癌症患者的方法以及预测癌症对 P2RX2 抑制剂治疗的反应的方法。
• Methods for treating cancer using GRM8 inhibitors
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US10683352B1

  公开（公告）日：2020-06-16

  The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

  本发明提供了使用mGluR8抑制剂（如mGluR8抑制抗体和小分子）治疗癌症的方法。本发明还包括含有 mGluR8 抑制剂的组合物、诊断 mGluR8 相关癌症患者的方法以及预测癌症对 mGluR8 抑制剂治疗的反应的方法。